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ABSTRACT
Objectives: Suboptimal compliance and failure to persist
with drug treatments are important determinants of thera-
peutic nonresponse and are of potential economic signiﬁ-
cance. The present article aims to describe the methodologies
that may be appropriate for integrating noncompliance and
nonpersistence in economic evaluations.
Methods: MEDLINE and NHS-EED were searched for eco-
nomic evaluations published in the period between 1997 and
2005. Articles were included if they explored the dependence
of cost-effectiveness results on varying levels of some form of
compliance-related measure. The different methodologies
used were reviewed and articles were appraised critically.
Alternative methodological approaches are proposed, illus-
trated by an example of the impact of different persistence
rates on a treatment’s cost-effectiveness.
Results: Ten articles were selected for inclusion. These were
generally scant on detail relating to how compliance/
persistence was assessed and what the impact was on health
outcomes. The methods used included Markov models and
decision analyses. Markov models allow for persistence to be
included directly in the analysis, as patients transit during
each cycle. Net-beneﬁt regression models are well suited
for analyzing prospective and retrospective studies where
patient-level data are available, whereas discrete event simu-
lations have the potential to offer more ﬂexibility.
Conclusions: Compliance and/or persistence are not included
routinely in pharmacoeconomic analyses, despite their poten-
tial impact. Where compliance and/or persistence are
included, a lack of methodological rigor and consistency in
deﬁnitions often limits the usefulness of the analyses. The
analytical techniques discussed in this article should serve as a
basis for developing guidelines on appropriate methodology.
Keywords: adherence, compliance, cost-effectiveness, eco-
nomic evaluation, persistence.
Introduction
Pharmacoeconomic evaluations assess whether incre-
mental improvements in outcome associated with a
given drug justify the cost. The speciﬁc nature of this
assessment can take various forms, but essentially
requires a comparison of alternative treatments’ costs
and beneﬁts. Many factors impact on these costs and
beneﬁts, one of which is how “well” the medicines are
taken. Suboptimal compliance and/or failure to persist
with therapy for the prescribed duration reduce the
therapeutic potential of drug treatment, and account
for many of the observed differences between efﬁcacy
and clinical effectiveness [1]. The purposes of this
article are to highlight the importance of integrating
compliance and persistence in pharmacoeconomic
analyses, to identify and appraise recent evaluations
that have integrated compliance and/or persistence,
and to develop recommendations on how pharmaco-
economic evaluations should integrate medication
noncompliance and nonpersistence, in line with stan-
dard economic evaluation methodological guidelines.
Deﬁnitions
There is great disparity in how compliance and persis-
tence are deﬁned, particularly in the health economic
literature [2]. Recently, the International Society of
Pharmacoeconomics & Outcomes Research (ISPOR)
special interest group on medication compliance and
persistence set out to standardize deﬁnitions and these
are summarized below.
Medication compliance (synonym: adherence), as
deﬁned by ISPOR, is “the extent to which a patient
acts in accordance with the prescribed interval, dose,
and dosing regimen. It is typically expressed as a
percentage of total number of doses taken (if pro-
spectively measured) or therapy-days available (if ret-
rospectively measured), in relation to the time period
of observation during which compliance is measured”
[3].
Medication persistence is “the length of time from
initiation to discontinuation of therapy and is mea-
sured in units of time” [3].
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Although not considered in these deﬁnitions or
in the present review, compliance has also to do with
patients’ quality of medicine taking, e.g., whether
medicines are taken with or after food, swallowed
whole and not chewed, and so forth. These are less
easily measured or quantiﬁed but for some medicines,
are of equal importance.
Impact of Compliance and Persistence on
Clinical Effectiveness
Since pharmacoeconomic evaluations assess the cost–
beneﬁt balance, the impact of poor compliance and
persistence on effectiveness is as important as the
impact on costs. Highly efﬁcacious medicine may have
poor clinical effectiveness unless taken, and taken
properly. The exact extent to which poor compliance
and persistence will affect clinical effectiveness is a
complicated issue, but a question that must be
addressed in any quantitative pharmacoeconomic
evaluation that wishes to take account of compliance
and persistence.
Any relationship between compliance, persistence,
and a medicine’s effectiveness relies on the fundamen-
tal premise that the medicine can work (i.e., is efﬁca-
cious). It is important to recognize that in some
instances, noncompliance may not always result in
clinically meaningful differences between efﬁcacy and
effectiveness. An example may include a drug that has
a long duration of action in relation to its dosing
interval, so that missing one or two doses may not be
so critical (e.g., atorvastatin, aspirin). This is referred
to as forgiveness, and is a measure of the ability of a
drug to maintain therapeutic activity despite the pres-
ence of noncompliance [4].
Impact of Compliance and Persistence on
Health-Care Resource Utilization and Costs
The impact of noncompliance and nonpersistence on
health-care resource utilization (HCRU) and, there-
fore, costs are likely to work in two ways:
1. The immediate and direct impact of poor
compliance/persistence on medicine acquisition
costs; and
2. The less immediate and indirect impact of poor
compliance/persistence on subsequent overall
HCRU associated with the condition being
treated, as a result of affecting clinical effective-
ness, and thus health outcomes as discussed
above. The contribution of adverse drug reactions
to noncompliance and nonpersistence, and their
impact on HCRU are also likely to feature.
Logically, poor compliance/persistence is likely to
reduce medicine acquisition costs, but increase subse-
quent overall HCRU. These two cost-drivers may well
thus be operating in opposite directions.
The impact on medicine acquisition costs is
determined most obviously by the extent of poor
compliance/persistence, i.e., a complete lack of com-
pliance and persistence will not cost much. Neverthe-
less, a more complex issue is how medicine acquisition
costs are generated in relation to medicine-taking
behaviors. For example, if poor persistence is mani-
fested by patients continuing to obtain prescriptions
but stockpiling their medicines, then poor persistence
will cost as much as perfect persistence. Further, the
overuse of medicines, itself a form of noncompliance,
may increase treatment costs.
The impact on subsequent overall HCRU will be
determined primarily by the level of impact on clinical
effectiveness, and on the relationship between effec-
tiveness and HCRU. For example, if a medicine is
highly “unforgiving” in relation to compliance, and
the HCRU associated with suboptimal management of
the condition is high, then the impact of poor compli-
ance on HCRU will be large.
Sokol et al. [5] conducted a retrospective cohort
study to evaluate the impact of medication noncom-
pliance on HCRU and costs for hypercholesterolemia,
diabetes, hypertension, and congestive heart failure in
137,277 patients in the United States. Compliance was
deﬁned as the number of days’ supply of maintenance
medications (expressed as a 1-year percentage),
obtained from administration claims data, for each
condition. For hypercholesterolemia and diabetes,
high levels of compliance (80–100%) were associated
with lower disease-related medical costs. Higher medi-
cation costs were more than offset by medical cost
reductions, producing an overall reduction in health-
care costs. For hypertension, there was a trend toward
lower medical costs at 80% to 100% compliance, but
this was not statistically signiﬁcant. No differences in
costs between compliance levels were evident for con-
gestive heart failure.
Controlling for demographic and socioeconomic
characteristics, increases in 12-month risk of hospital-
ization were evident in all four conditions as com-
pliance declined [5]. For diabetes, patients in the
80–100% compliance group had a 13% risk of
diabetes-related hospitalization, compared with 20%
in the 60–79% compliance group, and 24% in the
40–59% compliance group. Similarly, for hypertensive
patients, high levels of compliance (80–100%) were
associated with a reduced risk of hypertension-related
hospitalization (19%) compared with lower levels of
compliance (40–59% compliance, 24% risk). When
considering all-cause hospitalization, a more pro-
nounced difference was apparent, possibly an indica-
tion that noncompliance with one medication is
associated with noncompliance with other medications
for a comorbid condition.
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Compliance, Persistence, and
Pharmacoeconomics from the Perspectives of
the Pharmaceutical Industry and the
Health-Care Provider/Payer
From the perspective of the pharmaceutical industry,
compliance is becoming increasingly important for
product differentiation. By this we mean whether
manufacturers of product X can claim superiority over
competitor product Y on the basis of improved com-
pliance (as opposed to the traditional factors such as
efﬁcacy, safety, cost, and cost-effectiveness). This is
often accomplished by developing products that
require less frequent dosing which makes them more
patient-friendly, or that are administered by different
methods (e.g., injectable depot preparations compared
with oral) which can help to ensure compliance. These
include, among others, once-weekly and once-monthly
bisphosphonates for the treatment of postmenopausal
osteoporosis; long-acting transdermal, implantable,
and injectable hormonal contraceptives; and fort-
nightly injectable risperidone for the management of
schizophrenia. Moreover, combination preparations or
products that replace the need for taking an additional
medication to provide protection against the adverse
effects of a drug (e.g., gastroprotective agents
coprescribed with nonsteroidal antiinﬂammatory
drugs) may also help increase compliance.
Manufacturers of such preparations often seek to
demonstrate whether simpliﬁcation of the dosing regi-
mens result in better health outcomes [6] and how this
alters the cost-effectiveness of the product. This in
turn may allow positive reimbursement decisions and
increased market access, thus improving the commer-
cial success of these products. Nevertheless, factors
besides compliance are likely to affect the relationship
between dosing regimens, health outcomes and costs,
and these may not always favor the product [7].
Providers and payers of health care are increasingly
concerned about value for money. Nevertheless, the
extent to which patient compliance and persistence is
considered by decision-making authorities is unclear.
The National Institute for Health and Clinical Excel-
lence in the UK, for instance, considered compliance
and persistence as a determinant of cost-effectiveness
in their recent evaluation of long-acting reversible con-
traception [8], but not in the evaluation of newer drugs
for epilepsy in adults [9] or in the guidance on glita-
zones for patients with type 2 diabetes [10]. The selec-
tive incorporation of compliance and persistence in
some economic evaluations probably reﬂects a lack of
standardization in the guidance on health technology
appraisals for their consideration [11]. Data availabil-
ity is also an issue, particularly as information relating
to patients who discontinue treatment is almost never
reported or even collected. This makes it difﬁcult to
incorporate compliances into economic analyses, and
often requires broad assumptions be made. More com-
plete patient follow-up (e.g., comprehensive cohort
trial design), drug utilization data (such as administra-
tive claims databases in the United States), and com-
pliance measurements (such as electronic monitoring
devices) are necessary to facilitate data availability.
Empirical Evidence of the Impact
of Compliance and Persistence
on Cost-Effectiveness
The combined impact of noncompliance/
nonpersistence on both health outcomes and costs
requires the use of economic evaluations. Hughes et al.
[12] and Cleemput et al. [13] reviewed the literature
for pharmacoeconomic evaluations that considered
noncompliance and identiﬁed a need for better
methods for integrating noncompliance/persistence in
economic evaluations. Here, we describe an update of
the reviews to gain an insight as to whether approaches
of incorporating noncompliance into pharmacoeco-
nomic evaluations have improved since the original
publications. The present work, however, is not
intended to be a systematic review with full method-
ological rigor.
Methods
Pharmacoeconomic evaluations published between
1997 and June 2005 and which included (non)compli-
ance or (non)persistence as inputs in the evaluation
process were identiﬁed through searches of MEDLINE
and NHS-EED. Appropriate Boolean operators were
speciﬁed for pharmacological treatments to identify
articles that were common to the following two groups
of search terms:
1. references to a cost-effectiveness evaluation in the
title: cost-effective$, cost-utility; and
2. compliance, non-compliance, noncompliance,
adherence, non-adherence, nonadherence, persis-
tence, non-persistence, nonpersistence, discon-
tinuation, concordance.
No language restrictions were speciﬁed.
The search identiﬁed 84 articles, of which 21 were
retrieved after screening the abstracts. Of these, 10
reported how cost-effectiveness results changed
according to varying levels of some form of compli-
ance measure, and were included in the review.
Findings
All included evaluations considered pharmacological
treatments for chronic use, ranging from antipsychotic
medications to antituberculotic drugs. A summary of
the reviewed evaluations, details of the type of non-
compliance considered, and the impact of noncompli-
ance on the costs, effects, and cost-effectiveness results
is presented in Table 1.
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An explicit deﬁnition of compliance or persistence
was not given in all studies. Nevertheless, the measure
of compliance (or persistence) was provided in most
cases; therefore, it was possible to obtain an implicit
deﬁnition. The data sources for compliance or persis-
tence rates were based on relevant studies, randomized
controlled studies, or observational data. Edwards
et al. [14] based their analyses on electronic measure-
ment of medication bottle openings. In some cases,
patients were considered compliant above, and non-
compliant below, an arbitrary cutoff point. This
ranged from 50% to 93% without evidence justifying
the clinical relevance of the chosen value among the
articles reviewed [14,21].
The most important assumptions underlying these
studies are those relating noncompliance (or nonper-
sistence) to the effects and the costs of treatment. A few
studies had some supporting evidence for the link
between noncompliance and effects [14,18,22], but
others relied on simple assumptions, e.g., noncompli-
ant patients incurred no health beneﬁts [19,20,21,23].
The impact of noncompliance on costs, if accounted
for at all, was derived indirectly from the assumed
changes in effects [16,18,20,21].
Modeling in the Reviewed Evaluations
A variety of decision-analytic, Markov, and other
modeling techniques were used in the evaluations
(Table 1).
In the cases of decision-analysis models, the
branches of the decision trees represented different
levels of compliance, and probabilities were assigned
accordingly [14,18,19,20]. In the cost-effectiveness
analysis of various antipsychotic drugs, Edwards et al.
[14] speciﬁed three branches in the decision tree: com-
pliant, partially compliant, and noncompliant. Patients
had different levels of compliance with the evaluated
drugs, based on evidence from the literature. Relapse
rates in schizophrenia were speciﬁed as a function of
patient compliance and drug efﬁcacy, based on two
studies; one of which utilized the medication event
monitoring system, which is considered to be an objec-
tive method of assessing compliance.
In Markov models, dropping out was one of the
possible health states, and the transition probabilities
were determined by the discontinuation rates based on
a combination of randomized controlled trial (RCT)
and observed data [16,22]. Jasmer et al. [22] applied
different rates of completion to different durations of
isoniazid or isoniazid plus rifampin therapies in
patients with radiographic evidence of previous tuber-
culosis, and positive tuberculin test that had no prior
treatment. The reduction in the annual risk of tuber-
culosis varied according to how long patients contin-
ued with their respective therapies. The efﬁcacy of
varying durations of preventive strategy for tuberculo-
sis was based on a 5-year follow-up strategy (isoniazid)
and on assumptions (for the combination of isoniazid
plus rifampin).
In the pharmacoeconomic evaluation of drugs for
the management of urge incontinence associated with
overactive bladder, Hughes and Dubois [15] built an
empiric model that combined observational data on
the proportion of patients who remained on their
initially prescribed therapy with trial data on drug
efﬁcacy. In the base-case analysis, patients who discon-
tinued because of adverse effect were assumed to adopt
baseline disease characteristics and those who discon-
tinued as a result of experiencing some early health
beneﬁt were assumed to adopt placebo characteristics.
Some of the studies that were identiﬁed explored the
impact of varying compliance in sensitivity analyses
[17,18,23], and it is likely that there are other uniden-
tiﬁed pharmacoeconomic evaluations that did so as
well. Nevertheless, in general, there was a great deal of
inconsistency in the deﬁnitions adopted and methods
used, and no overall improvement is apparent since the
reviews of Hughes et al. [12] and Cleemput et al. [13].
These limitations make it difﬁcult to draw valid con-
clusions on the impact of noncompliance on the cost-
effectiveness of treatments, and to compare this across
different therapeutic areas.
Integrating Compliance and/or Persistence in
Pharmacoeconomic Evaluations
Since earlier studies have shown that deﬁnitions to be
inconsistent, and output inconclusive, the section that
follows describes different techniques that are suitable
for incorporating noncompliance and/or persistence in
pharmacoeconomic evaluations. Emphasis is placed on
approaches to modeling to improve methodological
rigor, with the choice of model being dependent on:
1. the condition being treated (e.g., acute vs.
chronic);
2. data availability (individual vs. aggregated data);
and
3. type of compliance (compliance vs. persistence).
Net-Beneﬁt Regression
When patient-level data are available on costs, health
outcomes, compliance and/or persistence, the most
comprehensive approach is to include a measure of
compliance as a covariate in a model of net monetary
beneﬁt—an extension to the framework suggested by
Hoch et al. [24]. This is one approach for analyzing
the results of an economic evaluation that has been
conducted alongside a prospective clinical trial.
The net-beneﬁt regression approach exploits the
linear nature of the net-beneﬁt statistic, which circum-
vents the disadvantages related to behavior of incre-
mental cost-effectiveness ratios when differences in
Noncompliance and Economic Evaluations 505
beneﬁts approach zero. For the individual, the net
monetary beneﬁt (NMB) is calculated as follows:
NMB E Ci i i= −λ
where l is used to denote the maximum willingness to
pay for an additional unit improvement in health
outcome, Ei and Ci are the observed effect and cost for
subject i. Within a regression framework, the contri-
bution of compliance and other explanatory variables
to the NMB may be calculated. Thus, for instance, the
NMB of a drug in patient i may be speciﬁed as follows:
NMB Age DRUGCompliance
DRUGPersistence
i i i i
i i
= + + +
+ +
α β β
β δ
1 2
3 . . . DRUGi i+ ε
Where a is an intercept term, bs are the coefﬁcients of
the regression relating to each covariate, and e is a
stochastic error term. DRUG represents a treatment
dummy, taking the value of 0 for the standard treat-
ment, and 1 for the test treatment. Interaction terms
that may include a time dimension, or both compliance
and persistence (for instance), may also be included in
the model. The regression coefﬁcients can be used to
estimate the incremental net beneﬁt of the drug at
varying levels of persistence and compliance; at 100%
compliance and persistence it would be d + b2 + b3.
Within such a framework, compliance would need to
be measured using a standardized metric that is the
strongest independent predictor of outcome and/or
cost.
The advantage of this approach is that the impact of
compliance on cost-effectiveness may be assessed at an
individual patient level, thereby providing a robust
estimate of population cost-effectiveness together with
fully characterized uncertainty. There are, however,
certain disadvantages to the net-beneﬁt regression
model, and these include the fact that both costs and
outcomes are analyzed concurrently. Greater power
may be afforded by explaining costs and effectiveness
separately. With regards to persistence, and in
common with other methods of survival analysis,
attention must be given to the phenomenon of censor-
ing: some patients may discontinue treatment prema-
turely after the time horizon of analysis.
Decision-Analytic Model
When a model is to be developed from existing pub-
lished sources of evidence, a decision-analytic model,
as described in some of the articles identiﬁed in the
literature review [14,18–20], is appropriate, particu-
larly for acute conditions. Branches of the decision
trees may be used to represent different levels of com-
pliance, which may be available from published
sources. This requires that an understanding is made of
the relationship between compliance and outcomes:
categorizing compliance into greater or equal to 80%
and less than 80%, is often not appropriate. Neverthe-
less, in most instances, differentiating patients to the
broad categories of compliers and noncompliers, or a
number of clusters with different levels of compliance,
based on tablet counts or electronic monitoring data, is
probably a reasonable approximation to make.
Discrete Event Simulation
Discrete event simulations (DES) are a form of model-
ing that observe the time-based (or dynamic) behavior
of a system, and are therefore potentially well suited to
analyzing the pharmacoeconomic impact of noncom-
pliance and nonpersistence [25]. DES speciﬁed with
patients as entities and treatment discontinuation as
events, allow the analyst to assign patient attributes,
which may alter depending on the occurrence of dis-
continuation. Modeling at the level of the individual
allows for continuous measures of compliance, and
greatly facilitates interactions between compliance and
time, as well as individual characteristics (e.g., compli-
ance with drugs for asthma may be highly correlated
with the severity of symptoms). No examples of the
use of DES to assess compliance or persistence have
been identiﬁed.
Markov Model
Hughes et al. [2] advocated a method for integrating
persistence in health economic evaluations by use of
a Markov model. Examples of the use of Markov
models were also identiﬁed in the literature review, and
are appropriate for chronic diseases where nonpersis-
tence is an issue. For each cycle in a model, a propor-
tion of patients who discontinue therapy experience a
higher risk of disease progression than those continu-
ing treatment.
This is illustrated with a simple hypothetical
example (Fig. 1) of a relatively inexpensive drug treat-
ment for a chronic condition that may be represented
by two health states “progressive” and “remissive.”
Progression from the remissive state to progressive
state is dependent on an annual transition probability,
Pt1. For those patients who discontinue treatment, Pt1
is assumed to increase—in other words, disease pro-
gression is accelerated in comparison with treated
patients. The probability of death from progressive
and remissive health states is represented by transi-
tional probabilities Pt2 and Pt3, respectively. These are
assumed to be independent of whether or not patients
continue treatment. The parameter estimates used in
the model are listed in Table 2.
Age-standardized life-table probabilities were
assumed for death in the remissive state [26]. The
results of the model show that over a lifetime, a cohort
of 100 hypothetical patients (which includes patients
who persist and those who discontinue), would accu-
mulate 58 less years of life, 94 less quality-adjusted
life-years (QALYs), but at £19,224 less cost (all undis-
counted) than a corresponding cohort of patients with
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100% persistence. The reduction in cost is owing to
fewer drugs being used as a consequence of nonpersis-
tence. Figure 2 illustrates the relationship between per-
sistence (%) at 5 years, and the changes in total health-
care costs, and disaggregated (drug and nondrug)
costs. Figure 3 presents changes in outcomes (life-years
gained and QALYs) that would be expected in a hypo-
thetical cohort of 100 patients with different persis-
tence rates.
The cost-effectiveness plane, obtained through plot-
ting differences in total cost against differences in out-
comes (QALYs), for different persistence rates, is
depicted in Figure 4. The origin in Figure 4 represents
100% persistence. For a hypothetical base-case sce-
nario of £1000 per annum in the progressive health
state, incremental changes in costs and outcomes,
resulting from reduced persistence, render the drug less
effective, and less costly at 5-year persistence rates
greater than 35%. At lower persistence rates, savings
in drug costs are outweighed by increases in nondrug
costs, resulting in a shift to the northwest quadrant of
the cost-effectiveness plane. It is evident from Figure 4
that the impact of nonpersistence on the cost-
effectiveness is sensitive to the costs of health care
associated with the progressive health state.
When developing a model that incorporates a
measure of persistence, data are required on health
outcomes and costs in patients who discontinue. If
costs are dependent on time in a health state and
duration of drug therapy, as in the illustrative example,
a model will require estimates of transition probabili-
ties that would be affected by drug discontinuation. In
the example, the transitional probability of advancing
from a remissive to a progressive health state, Pt1, in
patients “off therapy” may be regarded as being
equivalent to disease progression observed in the
placebo group of a RCT [15,27]. It is important,
however, to assess this in the light of any speciﬁc
reason why patients may not persist with treatment
and any trial inclusion/exclusion criteria that may not
be representative of the wider population [28].
Remissive
Progressive
Dead
Pt3
Pt1
Pt2
Persistence
Figure 1 Schematic representation of a Markov model representing a
disease with two health states, remissive and progressive, and death.
Transition among health states is determined by transition probabilities Pt1
(which is increased in patients who do not persist with treatment), Pt2 and
Pt3.
Table 2 Parameter estimates for the Markov model of the
impact of persistence on cost-effectiveness
Parameter Estimate
Age of entry to the model 45 years
Pt1 (patients on therapy) 10%
Pt1 (patients off therapy) 20%
Relative risk of death (progressive vs. remissive), Pt2/Pt3 2
Persistence (percentage of patients continuing at 5 years) 60%
Utility in “progressive” health state 0.7
Utility in “remissive” health state 0.9
Annual cost in “progressive” health state £1000
Annual cost in “remissive” health state £200
Annual drug cost £100
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and life-years gained.
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Statistical bias may therefore be introduced when
evidence on compliance and/or persistence is omitted
from pharmacoeconomic evaluations. Bias is also
introduced if compliance and/or persistence is incor-
rectly integrated, resulting from either problems of
deﬁnitions (e.g., not being speciﬁc whether percentage
compliance relates to percentage of patients who
persist, or percentage of prescriptions ﬁlled), or meth-
odological problems, for instance, if incorrect assump-
tions are made regarding the impact of noncompliance
(persistence) on health outcomes and costs.
The example illustrates that the lack of persistence
with effective therapies results in not only worsening of
health outcome, but also a change in cost-effectiveness.
A drug that is cost-effective when economic calcula-
tions are based on efﬁcacy studies is less likely to be
cost-effective when consideration is made of real-
world (effectiveness) utilization data on persistence.
Thus, a different decision on resource allocation may
be arrived when considering persistence in an eco-
nomic evaluation.
Conclusions and Recommendations
Compliance and persistence with drug therapies are
important determinants for successful management of
chronic conditions. They also impact on the economics
of disease management, in terms of both drug acqui-
sition costs and HCRU that may be associated with
drug side effects and the sequelae of the untreated
condition. Therefore, consideration of the effects of
noncompliance and nonpersistence should be an inte-
gral part of pharmacoeconomic evaluations and in the
health-care decision-making these evaluations inform.
Nevertheless, to date, the work in this is sparse, and
the limited evidence available has methodological limi-
tations. Further, the terms “compliance” and “persis-
tence” themselves have been variously and unclearly
speciﬁed, and a lack of consensus on their quantitative
measurement poses a challenge for analysts. Research
on the effects of compliance and persistence on real-life
clinical effectiveness and cost is inherently problem-
atic, and often seems to be the “poor cousin” of tra-
ditional randomized trials of efﬁcacy and safety. Lastly,
the development of economic modeling techniques to
investigate relative compliance and persistence is con-
sequently challenging; this is reﬂected in the results of
the literature search reported in this article, and the
lack of consensus guidelines from Health Technology
Assessment (HTA) bodies in this area.
Nevertheless, as reviewed in this article, a range of
approaches can, and have been applied to assessing the
pharmacoeconomic effects of compliance and persis-
tence. These include:
1. the possibility of designing prospective trials
with both compliance and persistence variables, in
addition to clinical and economic end points;
2. regression analyses of retrospective studies provid-
ing these same data;
3. modeling the extrapolated clinical and cost impact
of compliance and persistence; and
4. the subsequent decision-analytic model which
could synthesize information from any of these
methods.
The results of these analyses are of interest to a wide
range of stakeholders, from prescribers and patients,
to health-care policymakers, and the manufacturers of
these drugs. It is our recommendation that further
research in this ﬁeld is required, with one objective
being the development of formal HTA guidance
on appropriate methodology and standards. The
approaches described herein might serve as a basis for
developing such guidance.
This article is written by members of the International Society
for Pharmacoeconomics & Outcomes Research (ISPOR)
Economics of Medication Compliance Working Group, part
of the Medication Compliance and Persistence Special Inter-
est Group. The authors are very grateful for discussions with
other members of the Working Group, and for comments
from the associated Review Group.
References
1 Revicki DA, Frank L. Pharmacoeconomic evaluation
in the real world. Effectiveness versus efﬁcacy studies.
Pharmacoeconomics 1999;15:423–34.
2 Hughes DA, Bagust A, Haycox A, Walley T. Account-
ing for noncompliance in pharmacoeconomic evalua-
tions. Pharmacoeconomics 2001;19:1185–97.
90807060
50
0 102030 40
0
10
20
30
40
50
60
70
80
90
90
80
70
6050403020100 -200
-100
0
100
200
300
400
-140 -120 -100 -80 -60 -40 -20 0
Difference in QALYs
D
if
fe
re
n
ce
 in
 c
o
st
 (
£ 
th
o
u
sa
n
d
s)
£2000
£1000
£500
Figure 4 Cost-effectiveness plane, illustrating the impact of decreasing
the 5-year persistence from 100% (at the origin) to 0%. The analysis is
repeated, by use of sensitivity analysis, for annual costs in the “progressive”
health state of £500, £1000 (base case), and £2000.QALY, quality-adjusted
life-year.
508 Hughes et al.
3 Burrell A, Wong P, Ollendorf D, et al. Deﬁning
compliance/adherence and persistence. ISPOR Special
Interest Working Group. Value Health 2005;
8:A194–5.
4 Urquhart J. Patient non-compliance with drug regi-
mens: measurement, clinical correlates, economic
impact. Eur Heart J 1996;17(Suppl. A):S8–15.
5 Sokol MC, McGuigan KA, Verbrugge RR, Epstein
RS. Impact of medication adherence on hospitaliza-
tion risk and healthcare cost. Med Care 2005;43:521–
30.
6 Richter A, Anton SE, Koch P, Dennett SL. The impact
of reducing dose frequency on health outcomes. Clin
Ther 2003;25:2307–35.
7 Hughes D. Less is more: medicines that require less
frequent administration improve adherence, but are
they better? Pharmacoeconomics 2006;24:211–13.
8 National Institute for Health and Clinical Excellence
(NICE). Long-Acting Reversible Contraception, Clini-
cal Guideline No. 30. London: NICE, 2005.
9 National Institute for Health and Clinical Excellence
(NICE). Newer Drugs for Epilepsy in Adults, Tech-
nology Appraisal No. 76. London: NICE, 2004.
10 National Institute for Health and Clinical Excellence
(NICE). Guidance on the Use of Glitazones for the
Treatment of Type 2 Diabetes. Technology Appraisal
No. 63. London: NICE, 2003.
11 National Institute for Health and Clinical Excellence
(NICE). Guide to the Methods of Technology
Appraisal. London: NICE, 2004.
12 Hughes DA, Bagust A, Haycox A, Walley T. The
impact of non-compliance on the cost-effectiveness of
pharmaceuticals: a review of the literature. Health
Econ 2001;10:601–15.
13 Cleemput I, Kesteloot K, DeGeest S. A review of the
literature on the economics of noncompliance. Room
for methodological improvement. Health Policy
2002;59:65–94.
14 Edwards NC, Rupnow MF, Pashos CL, et al. Cost-
effectiveness model of long-acting risperidone in
schizophrenia in the US. Pharmacoeconomics
2005;23:299–314.
15 Hughes DA, Dubois D. Cost-effectiveness analysis of
extended-release formulations of oxybutynin and
tolterodine for the management of urge incontinence.
Pharmacoeconomics 2004;22:1047–59.
16 O’Brien BJ, Goeree R, Bernard L, et al. Cost-
Effectiveness of tolterodine for patients with urge
incontinence who discontinue initial therapy with
oxybutynin: a Canadian perspective. Clin Ther
2001;23:2038–49.
17 Chisholm D. Cost-effectiveness of ﬁrst-line antiepilep-
tic drug treatments in the developing world: a
population-level analysis. Epilepsia 2005;46:751–
9.
18 Hemels ME, Kasper S, Walter E, Einarson TR. Cost-
effectiveness of escitalopram versus citalopram in the
treatment of severe depression. Ann Pharmacother
2004;38:954–60.
19 Haby MM, Tonge B, Littleﬁeld L, et al. Cost-
effectiveness of cognitive behavioural therapy and
selective serotonin reuptake inhibitors for major
depression in children and adolescents. Aust NZ J
Psychiatry 2004;38:579–91.
20 Donnelly M, Haby MM, Carter R, et al. Cost-
effectiveness of dexamphetamine and methylpheni-
date for the treatment of childhood attention deﬁcit
hyperactivity disorder. Aust NZ J Psychiatry
2004;38:592–601.
21 Suarez PG, Floyd K, Portocarrero J, et al. Feasibility
and cost-effectiveness of standardised second-line
drug treatment for chronic tuberculosis patients:
a national cohort study in Peru. Lancet
2002;359:1980–9.
22 Jasmer RM, Snyder DC, Chin DP, et al. Twelve
months of isoniazid compared with four months of
isoniazid and rifampin for persons with radiographic
evidence of previous tuberculosis: an outcome and
cost-effectiveness analysis. Am J Respir Crit Care Med
2000;162:1648–52.
23 Cobos A, Jovell AJ, Garcia Altes A, et al. Which statin
is most efﬁcient for the treatment of hypercholester-
olemia? A cost-effectiveness analysis. Clin Ther
1999;21:1924–36.
24 Hoch JS, Briggs AH, Willan AR. Something old,
something new, something borrowed, something blue.
a framework for the marriage of health econometrics
and cost-effectiveness analysis. Health Econ 2002;
11:415–30.
25 Caro JJ. Pharmacoeconomic analyses using discrete
event simulation. Pharmacoeconomics 2005;23:323–
32.
26 The Government Actuary Department. Available
from: http://www.gad.gov.uk/Life_Tables/Interim_
Life_Tables.htm [Accessed September 2005].
27 Peterson AM, McGhan WF. Pharmacoeconomic
impact of non-compliance with statins. Pharmacoeco-
nomics 2005;23:13–25.
28 Pablos-Mendez A, Barr RG, Shea S. Run-in periods
in randomized trials: implications for the application
of results in clinical practice. JAMA 1998;279:
222–5.
Noncompliance and Economic Evaluations 509
